尽管投资活动喜忧参半，但 Elevance Health 的收益高于预期，维持“适度买入”评级。 Elevance Health beat earnings estimates despite mixed investment activity, maintaining a "Moderate Buy" rating.

Elevance Health， Inc. 在第四季度的投资活动喜忧参半。 Elevance Health, Inc. saw mixed investment activity in the fourth quarter. CDAM UK有限公司大幅度减少了股份,而Russell投资集团有限公司等其他公司则增加了股份。 CDAM UK Ltd significantly reduced its holdings, while other firms like Russell Investments Group Ltd increased theirs. Elevance Health 报告了强劲的季度业绩，超过了收益预期，并保持“适度买入”评级，目标价为 519.81 美元。 Elevance Health reported a strong quarterly performance, beating earnings estimates and maintaining a "Moderate Buy" rating with a target price of $519.81. 该公司从事健康福利和保险服务,市场上限为970.3亿美元。 The company, operating in health benefits and insurance services, has a market cap of $97.03 billion.